High transferability of neutralizing antibodies against SARS-CoV-2 to umbilical cord blood in pregnant women with BNT162b2 XBB.1.5 vaccine - a retrospective cohort study

Takuma Hayashi,Kenji Sano,Ikuo Konishi

DOI: https://doi.org/10.1101/2024.03.18.24304517

2024-03-19

Abstract:Coronavirus disease 2019 (COVID-19), when contracted by pregnant women, can lead to severe respiratory illness, rapid disease progression, and higher rates of intensive care unit admission. COVID-19 infection during pregnancy is associated with an increased risk of preterm delivery, cesarean section, fetal dysfunction, preeclampsia, and perinatal death. Additionally, vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from pregnant women to their fetuses has been observed. While severe infections in neonates and infants are rare, newborns can experience serious consequences from COVID-19, despite their suboptimal humoral immune system protection. The amino acids in the structural proteins of SARS-CoV-2 are subjected to constant mutation. Since around January 2023, COVID-19, caused by infection with omicron-type SARS-CoV-2 variants, has been prevalent globally. Omicron-type SARS-CoV-2 variants can evade the immune response triggered by traditional mRNA-based COVID-19 vaccines, such as BNT162b2. Therefore, vaccination with a vaccine (BNT162b2 XBB.1.5) that can provide protection against omicron-type SARS-CoV-2 variants is recommended. Therefore, we examined the titers of anti-spike glycoprotein of SARS-CoV-2 IgG and IgA in the blood and umbilical cord blood obtained from pregnant women vaccinated with BNT162b2 XBB.1.5. The results showed that anti-spike glycoprotein of SARS-CoV-2 IgG and IgA titers were highest in the blood and cord blood obtained from pregnant women vaccinated with BNT162b2 XBB.1.5 at late gestational age (28–34 weeks). No serious side effects or adverse events caused by vaccination of pregnant women with BNT162b2 XBB.1.5 were observed in either pregnant women or newborns. In the future, to validate our findings, large cohort clinical studies involving numerous pregnant women must be conducted.

Infectious Diseases (except HIV/AIDS)

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the levels of neutralizing antibodies (IgG and IgA) against the SARS - CoV - 2 spike glycoprotein in the blood and umbilical cord blood of pregnant women vaccinated with the BNT162b2 XBB.1.5 vaccine, in order to explore the immune effect of this vaccine in pregnant women and its protective effect on neonates. Specifically, the research focuses on the following points:

1. **Antibody transfer induced by the vaccine**: The study aims to determine whether the neutralizing antibodies produced in pregnant women after vaccination with the BNT162b2 XBB.1.5 vaccine can be effectively transferred to the umbilical cord blood of the fetus, thereby providing passive immune protection.

2. **Optimal vaccination time**: Explore the optimal timing of vaccination with the BNT162b2 XBB.1.5 vaccine during pregnancy to achieve the highest level of neutralizing antibodies and thus maximize the protective effect on neonates.

3. **Safety assessment**: Evaluate the safety of the BNT162b2 XBB.1.5 vaccine for pregnant women and neonates, including whether there are serious side effects or adverse events.

4. **Comparison of antibody levels**: Compare the research results in different countries, analyze the differences in the levels of neutralizing antibodies in the umbilical cord blood of pregnant women in Japan after vaccination with the BNT162b2 XBB.1.5 vaccine and those of pregnant women in the United States, and explore possible reasons.

Through these research objectives, the paper hopes to provide a scientific basis for formulating more effective vaccination strategies, especially in protecting the health of pregnant women and neonates during the epidemic.